SAGE THERAPEUTICS INC (SAGE) Stock Price, Quote, News and Overview
NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock
SAGE Quote and Key Statistics
SAGE THERAPEUTICS INC
NASDAQ:SAGE (1/21/2025, 8:25:25 PM)
After market: 6.94 0 (0%)6.94
-0.14 (-1.98%)
SAGE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.24% | ||
| ROE | -61.18% | ||
| Debt/Equity | 0 |
SAGE Performance and Technical Analysis
SAGE Ownership and Analysts
SAGE Latest News and Analysis
These stocks are moving in today's session
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Gapping stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
Stay updated with the stocks that are on the move in today's pre-market session.
Monday's pre-market session: top gainers and losers
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
About SAGE
Company Profile
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 487 full-time employees. The company went IPO on 2014-07-18. The firm has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The firm is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. The company is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Company Info
SAGE THERAPEUTICS INC
215 1st St
Cambridge MASSACHUSETTS 02142 US
CEO: Barry E. Greene
Employees: 487
Company Website: https://www.sagerx.com/
Investor Relations: https://investor.sagerx.com/
Phone: 16172998380
SAGE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |